Home > Newsletters > Clinical Trials Advisor > Bipartisan Bill Would Extend Exclusivity, Speed Review of Some Combo Drugs
Clinical Trials Advisor
Oct. 11, 2012 | Vol. 17 No. 20
Bipartisan Bill Would Extend Exclusivity, Speed Review of Some Combo Drugs
New fixed-dose drug combinations that include at least two INDs and target a serious or life-threatening disease could be eligible for an additional six months of marketing exclusivity and priority review under a new bipartisan-supported bill sponsored by Rep. Brian Bilbray (R-Calif.).
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.